Search

Your search keyword '"Visco C"' showing total 524 results
Start Over Author "Visco C"
524 results on '"Visco C"'

1. Primary Pancreatic Lymphoma: Recommendations for Diagnosis and Management

Author

Facchinelli D, Boninsegna E, Visco C, and Tecchio C

Subjects
primary pancreatic lymphoma, diffuse large b cell lymphoma, burkitt lymphoma, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Davide Facchinelli,1 Enrico Boninsegna,2 Carlo Visco,3 Cristina Tecchio3 1Hematology Unit, Ospedale San Bortolo, Vicenza, Italy; 2Department of Radiology, Azienda Socio Sanitaria Territoriale, Mantova, Italy; 3Hematology and Bone Marrow Transplant Unit, Department of Medicine, University of Verona, Verona, ItalyCorrespondence: Davide FacchinelliHematology Unit, Ospedale San Bortolo, Vicenza, ItalyEmail davide.facchinelli@aulss8.veneto.itBackground: Primary pancreatic lymphoma (PPL) is a rare disease representing 0.1% of all malignant lymphomas, which lacks well-defined diagnostic and therapeutic protocols. We conducted a systematic review to analyze demographic, diagnostic and therapeutic features of PPL.Methods: This review identified small series and single case reports. Sources were MEDLINE, PubMed, and the Cochrane library from January 2001 to December 2020. Data were screened, extracted and the risk of bias analyzed by three independent reviewers.Results: A total of 107 eligible papers (17 small series, 90 single case reports) describing 266 patients were identified. Patients had a median age of 53.1 (range 3– 86) years and were males in 64.6% of cases. Abdominal pain and jaundice were the most common presenting symptoms, affecting 75.3% and 41.8% of patients, respectively. PPL had a median size of 60.6 mm (range 16– 200) and it was localized in the pancreatic head in 63.7% of cases. At diagnosis most patients underwent ultrasonography followed by computed tomography. PPL typically showed low echogenicity, and lower contrast enhancement than solid tumors. Histopathological specimens were obtained by percutaneous or endoscopic biopsies in 47.7% of patients; abdominal surgery was performed in 33.5% of cases. Overall, diffuse large B-cell lymphoma was the most frequent histological diagnosis (53.6%). However, patients aged < 18 years were affected by Burkitt lymphoma in 52.4% of cases. Most patients (53.6%) received immunochemotherapy (IC) or IC plus radiotherapy (14%). Demolitive surgery appeared to be associated with impaired survival. Central nervous system (CNS) relapse or progression was observed in 20% of patients.Conclusion: PPL is a rare entity, with some peculiar features at modern imaging. For diagnostic purposes percutaneous or endoscopic biopsies might be preferable, as opposed to surgery. No definite data is available about the optimal treatment, which should be tailored on the histological type and associated with CNS prophylaxis.Keywords: primary pancreatic lymphoma, diffuse large B cell lymphoma, Burkitt lymphoma

Published
2021

2. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Author

Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., Visco C., Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., and Visco C.

Abstract

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

Published
2023

3. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia

Author

Mazzera, L, Abeltino, M, Lombardi, G, Cantoni, A, Jottini, S, Corradi, A, Ricca, M, Rossetti, E, Armando, F, Peli, A, Ferrari, A, Martinelli, G, Scupoli, M, Visco, C, Bonifacio, M, Ripamonti, A, Gambacorti-Passerini, C, Bonati, A, Perris, R, Lunghi, P, Mazzera L., Abeltino M., Lombardi G., Cantoni A. M., Jottini S., Corradi A., Ricca M., Rossetti E., Armando F., Peli A., Ferrari A., Martinelli G., Scupoli M. T., Visco C., Bonifacio M., Ripamonti A., Gambacorti-Passerini C., Bonati A., Perris R., Lunghi P., Mazzera, L, Abeltino, M, Lombardi, G, Cantoni, A, Jottini, S, Corradi, A, Ricca, M, Rossetti, E, Armando, F, Peli, A, Ferrari, A, Martinelli, G, Scupoli, M, Visco, C, Bonifacio, M, Ripamonti, A, Gambacorti-Passerini, C, Bonati, A, Perris, R, Lunghi, P, Mazzera L., Abeltino M., Lombardi G., Cantoni A. M., Jottini S., Corradi A., Ricca M., Rossetti E., Armando F., Peli A., Ferrari A., Martinelli G., Scupoli M. T., Visco C., Bonifacio M., Ripamonti A., Gambacorti-Passerini C., Bonati A., Perris R., and Lunghi P.

Abstract

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR’s tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCRY360/Y177, BCR::ABL1Y360/Y177 and cytoplasmic ABL1Y412/T735 dephosphorylation thereby provoking the rescue of the BCR’s anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia. [Figure not available: see fulltext.].

Published
2023

5. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., Merli F., Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., and Merli F.

Abstract

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n 5 388) or required hospitalization (n 5 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

Published
2022

7. Immunotherapy: AUTOLOGOUS CYTOKINE-INDUCED KILLER (CIK) CELLS COMBINED WITH ANTI CD20 ANTIBODY FOR B-CELL MALIGNANCIES: FIRST REPORT ON CLINICAL FEASIBILITY

Author

Elice, F., primary, Riva, M., additional, Bernardi, M., additional, Bozza, A., additional, Cappuzzello, E., additional, Catanzaro, D., additional, Chieregato, K., additional, Dalla Pietà, A., additional, Krampera, M., additional, Merlo, A., additional, Piazza, F., additional, Sommaggio, R., additional, Tisi, M., additional, Trentin, L., additional, Visco, C., additional, Visentin, A., additional, Tosetto, A., additional, Rosato, A., additional, and Astori, G., additional

Published
2023
Full Text
View/download PDF

8. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Author

Xia, Y, Xu-Monette, Z Y, Tzankov, A, Li, X, Manyam, G C, Murty, V, Bhagat, G, Zhang, S, Pasqualucci, L, Visco, C, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Richards, K L, Hsi, E D, Choi, W W L, van Krieken, J H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Winter, J N, Piris, M A, Westin, J, Fowler, N, Miranda, R N, Ok, C Y, Li, Y, Li, J, Medeiros, L J, and Young, K H

Published
2017
Full Text
View/download PDF

10. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Author

Arcaini, L., Vallisa, D., Rattotti, S., Ferretti, V.V., Ferreri, A.J.M., Bernuzzi, P., Merli, M., Varettoni, M., Chiappella, A., Ambrosetti, A., Tucci, A., Rusconi, C., Visco, C., Spina, M., Cabras, G., Luminari, S., Tucci, M., Musto, P., Ladetto, M., Merli, F., Stelitano, C., d'Arco, A., Rigacci, L., Levis, A., Rossi, D., Spedini, P., Mancuso, S., Marino, D., Bruno, R., Baldini, L., and Pulsoni, A.

Published
2014
Full Text
View/download PDF

11. ADVANCING ACADEMIC CAPACITY IN PHYSICAL AND REHABILITATION MEDICINE TO STRENGTHEN REHABILITATION IN HEALTH SYSTEMS WORLDWIDE: A JOINT EFFORT BY THE EUROPEAN ACADEMY OF REHABILITATION MEDICINE, THE ASSOCIATION OF ACADEMIC PHYSIATRISTS, AND THE INTERNATIONAL SOCIETY OF PHYSICAL AND REHABILITATION MEDICINE

Author

Frontera W. R., Stucki G., Engkasan J. P., Francisco G. E., Gutenbrunner C., Hasnan N., Lains J., Yusof Y. M., Negrini S., Omar Z., Battistella L. R., Sowa G., Stam H., Bickenbach J., Deltombe T., Didier J. -P., Malmivaara A., Mc-Namara A., Michail X., Paysant J., Rietman H., Vanderstraeten G., Ward A. B., Celnik P., Cuccurullo S. J., Fredericson M., Kowalske K., Lee M., Morgenroth D., Moroz A., Patel C., Powell D., Raghavan P., Stein A., Visco C., Wilson R., Gimigliano F., Laffont I., Li L., Schiappacasse C., Frontera, W. R., Stucki, G., Engkasan, J. P., Francisco, G. E., Gutenbrunner, C., Hasnan, N., Lains, J., Yusof, Y. M., Negrini, S., Omar, Z., Battistella, L. R., Sowa, G., Stam, H., Bickenbach, J., Deltombe, T., Didier, J. -P., Malmivaara, A., Mc-Namara, A., Michail, X., Paysant, J., Rietman, H., Vanderstraeten, G., Ward, A. B., Celnik, P., Cuccurullo, S. J., Fredericson, M., Kowalske, K., Lee, M., Morgenroth, D., Moroz, A., Patel, C., Powell, D., Raghavan, P., Stein, A., Visco, C., Wilson, R., Gimigliano, F., Laffont, I., Li, L., Schiappacasse, C., and Rehabilitation Medicine

Subjects
Science & Technology, Rehabilitation, Physical Therapy, Sports Therapy and Rehabilitation, General Medicine, Physical and Rehabilitation Medicine, Physiatrists, Academic Capacity, Settore MED/34 - Medicina Fisica e Riabilitativa, Medicine, Humans, Life Sciences & Biomedicine, Physical Examination, Sport Sciences
Abstract

ispartof: AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION vol:101 issue:9 pages:897-904 ispartof: location:United States status: published

Published
2022

12. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Author

Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., Vannucchi A. M., Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., and Vannucchi A. M.

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

Published
2021

13. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

Author

Deng, L, Xu-Monette, Z Y, Loghavi, S, Manyam, G C, Xia, Y, Visco, C, Huh, J, Zhang, L, Zhai, Q, Wang, Y, Qiu, L, Dybkær, K, Chiu, A, Perry, A M, Zhang, S, Tzankov, A, Rao, H, Abramson, J, Sohani, A R, Xu, M, Hsi, E D, Zhu, J, Ponzoni, M, Wang, S, Li, Ling, Zhang, M, Ferreri, A J M, Parsons, B M, Li, Y, Piris, M A, Medeiros, L J, and Young, K H

Published
2016
Full Text
View/download PDF

15. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., Corradini P., Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., and Corradini P.

Abstract

Background: Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods: This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and the prospective part of the study is ongoing. Findings: We enrolled 536 patients with a median follow-up of 20 days (IQR 10–34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77–2·34) in our whole study cohort and 3·72 (2·86–4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1–44·9). Older age (hazard ratio 1·03, 95% CI 1·01–1·05); progressive disease status (2·10, 1·41–3·12); diagnosis of

Published
2020

17. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Author

Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., Foa R., Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., and Foa R.

Abstract

NA

Published
2022

19. Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper

Author

Bailly, S, Cartron, G, Chaganti, S, Cordoba, R, Corradini, P, Dull, J, Ferrarini, I, Osborne, W, Rosenwald, A, Sancho, JM, Tilly, H, Van den Neste, E, Viardot, A, and Visco, C

Subjects
relapsed, refractory, CD19, non-Hodgkin lymphoma, diffuse large B-cell lymphoma
Abstract

The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.

Published
2022

20. VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE

Author

Galimberti, S, Marchi E, Pelosini, M, Benedetti, E, Urso, A, Cuneo, A, Musuraca, G, Martinelli, G, Quaglia, FM, Visco, C, Vallone, R, Muzi, C, Cairoli, R, Loseto, G, Guarini, A, Clerico, M, Ferrero, S, Petrini, M, Galimberti, S, Marchi, E, Pelosini, M, Benedetti, E, Urso, A, Cuneo, A, Musuraca, G, Martinelli, G, Quaglia, F, Visco, C, Vallone, R, Muzi, C, Cairoli, R, Loseto, G, Guarini, A, Clerico, M, Ferrero, S, and Petrini, M

Subjects
Hematology
Published
2021

22. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

Author

Mian, M., Capello, D., Ventre, M. B., Grazio, D., Svaldi, M., Rossi, A., Tsang, R., Gospodarowicz, M. K., Oldani, E., Federico, M., Luminari, S., Marcheselli, L., Pogliani, E. M., Rossini, F., Cabrera, M. E., Martelli, M., Gutierrez-Garcia, G., Busetto, M., Visco, C., Fiegl, M., Rossi, D., Gaidano, G., Cavalli, F., Zucca, E., Rambaldi, A., Cortelazzo, S., and on behalf of the International Extranodal Lymphoma Study Group (IELSG)

Published
2014
Full Text
View/download PDF

23. TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA

Author

Villa, D., primary, Jiang, A., additional, Crosbie, N., additional, Rule, S., additional, McCulloch, R., additional, Visco, C., additional, Buege, M. J., additional, Kumar, A., additional, Bond, D., additional, Paludo, J., additional, Maurer, M. J., additional, Thanarajasingam, G., additional, Baech, J., additional, El‐Galaly, T., additional, Kugathasan, L., additional, Gerrie, A. S., additional, and Lewis, D., additional

Published
2021
Full Text
View/download PDF

24. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

Author

Conconi, A., primary, Vannata, B., additional, Janikova, A., additional, Ramirez, A., additional, Bodoni, C. Lobetti, additional, Nowakowski, G., additional, Mian, M., additional, Ferreri, Andrés J.M., additional, Ryan, G., additional, Pangalis, G. A., additional, Cabrera, M. E., additional, Luminari, S., additional, Montoto, S., additional, Tsang, R., additional, Aurer, I., additional, Visco, C., additional, Mazzucchelli, L., additional, Trneny, M., additional, Gaidano, G., additional, Federico, M., additional, Lopez‐Guillermo, A., additional, Pro, B., additional, and Zucca, E., additional

Published
2021
Full Text
View/download PDF

25. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Author

Merli, M., primary, Rattotti, S., additional, Spina, M., additional, Re, F., additional, Motta, M., additional, Piazza, F., additional, Orsucci, L., additional, Ferreri, Andrés J.M., additional, Perbellini, O., additional, Dodero, A., additional, Vallisa, D., additional, Pulsoni, A., additional, Santoro, A., additional, Zuccaro, V., additional, Chimienti, E., additional, Russo, F., additional, Visco, C., additional, Zignego, A. L., additional, Marcheselli, L., additional, Luminari, S., additional, Paulli, M., additional, Bruno, R., additional, and Arcaini, L., additional

Published
2021
Full Text
View/download PDF

26. LYMFOREST‐25: PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELS

Author

Orgueira, A. Mosquera, primary, López, M. Cid, additional, Raindo, A. Peleteiro, additional, Díaz Arias, J. Án., additional, Pérez, M. S. González, additional, Rodríguez, B. Antelo, additional, Pérez, L. Bao, additional, Ferro, R. Ferreiro, additional, Santos, C. Aliste, additional, Encinas, M. M. Pérez, additional, Rodríguez, M. F. Fraga, additional, Xu‐Monette, Z., additional, Visco, C., additional, Young, K., additional, and López, J. L. Bello, additional

Published
2021
Full Text
View/download PDF

27. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

Bonfiglio, F., primary, Bruscaggin, A., additional, Guidetti, F., additional, Terzi di Bergamo, L., additional, Faderl, M., additional, Spina, V., additional, Condoluci, A., additional, Bonomini, L., additional, Forestieri, G., additional, Koch, R., additional, Piffaretti, D., additional, Pini, K., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Arribas, A., additional, Lucioni, M., additional, Ghilardi, G., additional, Wu, W., additional, Arcaini, L., additional, Baptista, M. J., additional, Bastidas, G., additional, Bea, S., additional, Boldorini, R., additional, Broccoli, A., additional, Canzonieri, V., additional, Cascione, L., additional, Ceriani, L., additional, Cogliatti, S., additional, Derenzini, E., additional, Devizzi, L., additional, Dietrich, S., additional, Elia, A. R., additional, Facchetti, F., additional, Gaidano, G., additional, Garcia, J. F., additional, Gerber, B., additional, Ghia, P., additional, Silva, M. G., additional, Gritti, G., additional, Guidetti, A., additional, Hitz, F., additional, Inghirami, G., additional, Ladetto, M., additional, Lopez‐Guillermo, A., additional, Lucchini, E., additional, Maiorana, A., additional, Marasca, R., additional, Matutes, E., additional, Meignin, V., additional, Merli, M., additional, Moccia, A., additional, Mollejo, M., additional, Montalban, C., additional, Novak, U., additional, Oscier, D. G., additional, Passamonti, F., additional, Piazza, F., additional, Pizzolitto, S., additional, Sabattini, E., additional, Salles, G., additional, Santambrogio, E., additional, Scarfó, L., additional, Stathis, A., additional, Stüssi, G., additional, Geyer, J. T., additional, Tapia, G., additional, Thieblemont, C., additional, Tousseyn, T., additional, Tucci, A., additional, Visco, C., additional, Vitolo, U., additional, Zenz, T., additional, Zinzani, P. L., additional, Khiabanian, H., additional, Calcinotto, A., additional, Bertoni, F., additional, Bhagat, G., additional, Campo, E., additional, Leval, L., additional, Dirnhofer, S., additional, Pileri, S. A., additional, Piris, M. Án., additional, Traverse‐Glehen, A., additional, Tzankov, A., additional, Paulli, M., additional, Ponzoni, M., additional, Mazzucchelli, L., additional, Cavalli, F., additional, Zucca, E., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

28. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

Author

Pieta, A. D., Cappuzzello, E., Palmerini, P., Ventura, A., Visentin, A., Astori, G., Chieregato, K., Mozzo, V., Perbellini, O., Tisi, M. C., Trentin, L., Visco, C., Ruggeri, M., Sommaggio, R., and Rosato, A.

Subjects
Clinical/Translational Cancer Immunotherapy, Lymphoma, B-Cell, combined modality therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Humanized, adoptive, hematologic neoplasms, immunotherapy, Mice, Antineoplastic Agents, Immunological, Cytokine-Induced Killer Cells, Mice, Inbred NOD, Animals, Humans, Female, RC254-282, Aged
Abstract

Background Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells, but several limits still restrain the administration to a limited proportion of patients. This unmet clinical need might be fulfilled by an adoptive immunotherapy approach that combines cytokine-induced killer (CIK) cells and monoclonal antibodies (mAb) to the CD20 antigen. Indeed, CIK cells are an effector population endowed with antitumor activity, which can be further improved and antigen-specifically redirected by clinical-grade mAb triggering antibody-dependent cell-mediated cytotoxicity. Methods CIK cells were generated from peripheral blood of patients affected by different B-cell malignancies using a blinatumomab-based cell culture protocol. Effector cells were combined with the anti-CD20 mAb obinutuzumab and their therapeutic activity was assessed both in vitro and in vivo. Results CIK cells were successfully expanded in clinically relevant numbers, starting from small volumes of peripheral blood with extremely low CD3+ counts and high tumor burden. This relied on the addition of blinatumumab in culture, which leads to the simultaneous expansion of effector cells and the complete elimination of the neoplastic component. Moreover, CIK cells were highly cytotoxic in vitro against both B-cell tumor cell lines and autologous neoplastic targets, and had a significant therapeutic efficacy against a B-cell malignancy patient-derived xenograft on in vivo transfer. Conclusions The combination of an easily expandable CIK cell effector population with a mAb already in clinical use establishes a tumor antigen-specific redirection strategy that can be rapidly translated into clinical practice, providing an effective therapeutic alternative for B-cell malignancies without any need for genetic modifications. Additionally, the approach can be potentially applied to an extremely vast array of different tumors by simply substituting the targeting mAb.

Published
2021

29. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Author

Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M. G. D., Bruna, R., Coviello, E., Romano, I., Cairoli, R., Lemoli, R., Farina, F., Venditti, A., Busca, A., Ladetto, M., Massaia, M., Pinto, A., Arcaini, L., Tafuri, A., Marchesi, F., Fracchiolla, N., Bocchia, M., Armiento, D., Candoni, A., Krampera, M., Luppi, M., Cardinali, V., Galimberti, S., Cattaneo, C., La Barbera, E. O., Mina, R., Lanza, F., Visani, G., Musto, P., Petrucci, L., Zaja, F., Grossi, P. A., Bertu, L., Pagano, Livio, Corradini, P., Derenzini, E., Marchetti, M., Scattolin, A. M., Corso, A., Tosi, P., Gherlinzoni, F., Passerini, C. G., Cavo, M., Fava, C., Turrini, M., Visco, C., Zappasodi, P., Merli, M., Mora, B., Vannucchi, A. M., Pagano L. (ORCID:0000-0001-8287-928X), Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M. G. D., Bruna, R., Coviello, E., Romano, I., Cairoli, R., Lemoli, R., Farina, F., Venditti, A., Busca, A., Ladetto, M., Massaia, M., Pinto, A., Arcaini, L., Tafuri, A., Marchesi, F., Fracchiolla, N., Bocchia, M., Armiento, D., Candoni, A., Krampera, M., Luppi, M., Cardinali, V., Galimberti, S., Cattaneo, C., La Barbera, E. O., Mina, R., Lanza, F., Visani, G., Musto, P., Petrucci, L., Zaja, F., Grossi, P. A., Bertu, L., Pagano, Livio, Corradini, P., Derenzini, E., Marchetti, M., Scattolin, A. M., Corso, A., Tosi, P., Gherlinzoni, F., Passerini, C. G., Cavo, M., Fava, C., Turrini, M., Visco, C., Zappasodi, P., Merli, M., Mora, B., Vannucchi, A. M., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

Published
2021

30. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Author

Visco, C, Li, Y, Xu-Monette, Z Y, Miranda, R N, Green, T M, Li, Y, Tzankov, A, Wen, W, Liu, W-m, Kahl, B S, d'Amore, E S G, Montes-Moreno, S, Dybkær, K, Chiu, A, Tam, W, Orazi, A, Zu, Y, Bhagat, G, Winter, J N, Wang, H-Y, O'Neill, S, Dunphy, C H, Hsi, E D, Zhao, X F, Go, R S, Choi, W W L, Zhou, F, Czader, M, Tong, J, Zhao, X, van Krieken, J H, Huang, Q, Ai, W, Etzell, J, Ponzoni, M, Ferreri, A J M, Piris, M A, Møller, M B, Bueso-Ramos, C E, Medeiros, L J, Wu, L, and Young, K H

Published
2012
Full Text
View/download PDF

32. Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Author

Varettoni, M., Ferrari, A., Frustaci, A. M., Ferretti, V. V., Rizzi, R., Motta, M., Piazza, F., Merli, M., Benevolo, G., Visco, C., Laurenti, L., Ferrero, S., Gentile, M., Del Fabro, V., Abbadessa, A., Klersy, C., Musto, P., Fabbri, N., Deodato, M., Dogliotti, I., Greco, C., Corbingi, A., Luminari, S., Arcaini, L., Rizzi R., Piazza F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Varettoni, M., Ferrari, A., Frustaci, A. M., Ferretti, V. V., Rizzi, R., Motta, M., Piazza, F., Merli, M., Benevolo, G., Visco, C., Laurenti, L., Ferrero, S., Gentile, M., Del Fabro, V., Abbadessa, A., Klersy, C., Musto, P., Fabbri, N., Deodato, M., Dogliotti, I., Greco, C., Corbingi, A., Luminari, S., Arcaini, L., Rizzi R., Piazza F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), and Gentile M.

Abstract

We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With a median follow-up of 5.6 years, 57% have been treated. As initial therapy 79% of patients received chemo-immunotherapy, 13% a chemo-free induction and 8% chemotherapy only. At relapse or progression, 6% underwent an autologous stem cell transplantation. Overall, 19% of patients received ibrutinib during the course of the disease. According to IPSSWM, 63% were classified as low risk, 27% as intermediate risk and 10% as high risk. Five-year OS was shorter in high-risk as compared with low or intermediate risk patients (92.9% vs 100% P =.002). According to revised IPSSWM, 92% were classified as very low or low risk and 8% as intermediate risk, with a shorter 5-year OS in the latter group (87.5% vs 100%, P =.028). The OS of young WM patients was not significantly reduced as compared with age-matched, sex-matched and calendar year-matched general population. Early diagnosis, absence of high-risk features in symptomatic patients and high efficacy of modern treatments are the main determinants of the excellent outcome of young WM patients.

Published
2020

43. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, A, Follows, G, Rigolin, GM, Piciocchi, A, Tedeschi, A, Trentin, L, Perez, AM, Coscia, M, Laurenti, L, Musuraca, G, Farina, L, Delgado, AR, Orlandi, EM, Galieni, P, Mauro, FR, Visco, C, Amendola, A, Billio, A, Marasca, R, Chiarenza, A, Meneghini, V, Ilariucci, F, Marchetti, M, Molica, S, Re, F, Gaidano, G, Gonzalez, M, Forconi, F, Ciolli, S, Cortelezzi, A, Montillo, M, Smolej, L, Schuh, A, Eyre, TA, Kennedy, B, Bowles, KM, Vignetti, M, de la Seam, J, Moreno, C, Foa, R, Ghia, P, GIMEMA, European Res Initiative CLL ERIC, and UK CLL Forum

Abstract

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398)

Published
2018

44. OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY

Author

Visco, C., primary, Di Rocco, A., additional, Tisi, M.C., additional, Morello, L., additional, Evangelista, A., additional, Zilioli, V.R., additional, Rusconi, C., additional, Hohaus, S., additional, Sciarra, R., additional, Re, A., additional, Tecchio, C., additional, Chiappella, A., additional, Marin-Niebla, A., additional, McCulloch, R., additional, Gini, G., additional, Perrone, T., additional, Nassi, L., additional, Pennese, E., additional, Stefani, P.M., additional, Cox, M.C., additional, Bozzoli, V., additional, Fabbri, A., additional, Polli, V., additional, Ferrero, S., additional, De Celis, I.A., additional, Sica, A., additional, Arcaini, L., additional, Balzarotti, M., additional, Rule, S., additional, and Vitolo, U., additional

Published
2019
Full Text
View/download PDF

45. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B-CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Gini, G., primary, Tani, M., additional, Bassan, R., additional, Tucci, A., additional, Ballerini, F., additional, Sampaolo, M., additional, Merli, F., additional, Re, F., additional, Annibali, O., additional, Liberati, A., additional, Visco, C., additional, Arcari, A., additional, Storti, S., additional, Fabbri, A., additional, Musuraca, G., additional, Zilioli, V., additional, Cox, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

47. IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA

Author

Rusconi, C., primary, Tucker, D., additional, Bernard, S., additional, Muzi, C., additional, Crucitti, L., additional, Stefani, P., additional, Cox, M., additional, Gini, G., additional, Re, A., additional, Sciarra, R., additional, Liberati, A., additional, Morello, L., additional, Arcari, A., additional, Mannina, D., additional, Vitagliano, O., additional, Sartori, R., additional, Chiappella, A., additional, Balzarotti, M., additional, Vitolo, U., additional, Thieblemont, C., additional, Rule, S., additional, and Visco, C., additional

Published
2019
Full Text
View/download PDF

48. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY

Author

Bruscaggin, A., primary, Mollejo, M., additional, Tapia, G., additional, Gomes da Silva, M., additional, Novak, U., additional, Dietrich, S., additional, Ponzoni, M., additional, Rambaldi, A., additional, Corradini, P., additional, Vitolo, U., additional, Merli, M., additional, Tzankov, A., additional, Cogliatti, S., additional, Montalban, C., additional, Marasca, R., additional, de Leval, L., additional, Visco, C., additional, Baptista, M.J., additional, Tousseyn, T., additional, Facchetti, F., additional, Paulli, M., additional, Mazzucchelli, L., additional, Bea, S., additional, Oscier, D., additional, Zinzani, P., additional, Bhagat, G., additional, Inghirami, G., additional, Gaidano, G., additional, Traverse-Glehen, A., additional, Thieblemont, C., additional, Piris, M.A., additional, Cavalli, F., additional, Arcaini, L., additional, Zucca, E., additional, and Rossi, D., additional

Published
2019
Full Text
View/download PDF

49. PS1090 OBINUTUZUMAB DOES NOT COMPROMISE MOBILIZATION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN LYMPHOMA PATIENTS: RESULTS FROM A FIL PROSPECTIVE PHASE II STUDY (THE GIOTTO STUDY)

Author

Battistini, R., primary, Kovalchk, S., additional, Zoli, V., additional, Puccini, B., additional, Arcaini, L., additional, Flenghi, L., additional, Martelli, M., additional, Visco, C., additional, Mian, M., additional, Evangelista, A., additional, Gotti, M., additional, Mannelli, L., additional, Bassan, R., additional, Palombi, F., additional, Pozzi, S., additional, Rosa, L. De, additional, and Rigacci, L., additional

Published
2019
Full Text
View/download PDF

50. PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE

Author

Facchinelli, D., primary, Boninsegna, E., additional, Sina, S., additional, Borin, A., additional, Tisi, M., additional, Piazza, F., additional, Scapinello, G., additional, Maiolo, E., additional, Merli, M., additional, Stefani, P., additional, Basso, M., additional, Parisi, A., additional, Manfrin, E., additional, Krampera, M., additional, Visco, C., additional, and Tecchio, C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results